Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 09

628P - Infection-related hospitalization and overall survival with primary prophylaxis for febrile neutropenia in patients with diffuse large B-cell lymphoma treated with R-CHOP: A nationwide population-based study


10 Sep 2022


Poster session 09


Tumour Site

Haematological Malignancies


Moonho Kim


Annals of Oncology (2022) 33 (suppl_7): S283-S294. 10.1016/annonc/annonc1055


M. Kim1, Y. Ahn1, H. Ahn1, S. Yi2

Author affiliations

  • 1 Department Of Hematology And Oncology, Gangneung Asan Hospital, University of Ulsan College of Medicine, 25540 - Gangneung/KR
  • 2 Department Of Preventive Medicine And Public Health, Catholic Kwandong University International St. Mary's Hospital, 404-834 - Incheon/KR

Abstract 628P


Febrile neutropenia (FN) and chemotherapy-induced neutropenia (CIN) are common conditions involving dose reduction or delayed chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL). Owing to the lack of real-word data on the effectiveness of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)-based primary prophylaxis (PP) in literature, we aimed to investigate the effects of PP with R-CHOP on the incidence of FN/CIN-related hospitalizations, overall survival (OS), and length of hospital stay in DLBCL patients.


A population-based cohort study of 11,491 DLBCL patients who underwent R-CHOP during 2010-2016 was conducted using data from the National Health Insurance Service.


PP was introduced to South Korea in 2014. R-CHOP-based PP reduced infection-related hospitalizations by 16% compared with the same treatment before reimbursement (hazard ratio [HR]=0.84, P<0.001). By year, infection-related hospitalizations in patients who received PP from 2014 to 2016 significantly decreased in terms of the HR to 0.79, 0.87, and 0.78, respectively, compared with those in patients who received PP in 2013 (P<0.001; P=0.002; and P<0.001). Length of hospital stays decreased by 4.4, 4.0, and 2.3 days from 2014 to 2016 compared with that in 2013 in patients receiving PP (P=0.024, P=0.009, and P=0.076). However, PP did not show any significant difference in 5-year OS rates (HR=0.97, P=0.474).


The introduction of PP with R-CHOP in DLBCL did not provide any significant benefit in OS; however, it lowered the risk of infection-related hospitalization and shortened the length of hospital stay. This is the first study to use real-world data from the National Health Insurance Service on PP for DLBCL patients with FN/CIN.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Moonho Kim.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.